Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment

Cooperberg, Matthew R.; Broering, Jeannette M.; Kantoff, Philip W.; Carroll, Peter R.

doi:10.1016/j.juro.2007.03.135

« Previous Next »The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S14-S19, September 2007

Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment

Matthew R. Cooperberg
- Financial interest and/or other relationship with TAP Pharmaceuticals.
Jeannette M. Broering
- Financial interest and/or other relationship with TAP Pharmaceuticals.
Philip W. Kantoff
- Financial interest and/or other relationship with Abbott, Pfizer, Aventis, AstraZeneca, Bristol Myers Squibb, TAP Pharmaceuticals, Amgen, Novartis, Bayer, GlaxoSmithKline, Therion Biologies, Wilex, Genentech and Genzyme.
Peter R. Carroll
- Correspondence: University of California-San Francisco/Mt. Zion Cancer Center, 1600 Divisadero St., 3rd Floor, San Francisco, California 94115-1711 (telephone: 415-353-7098; FAX: 415-353-7093).
- Financial interest and/or other relationship with National Institutes of Health/National Cancer Institute, Department of Defense, TAP Pharmaceuticals, InforMEDical and Strategic Education Physician Academy.

Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, and Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

published online 18 July 2007.